Assignee
ZYMEWORKS INC
CA·45 granted patents·31 pending applications·335 citations·filing 2006–2022
Top patents by PatentIndex Score
76 records- 0197US9499634B2Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cellsZYMEWORKS INC·Filed 2013·Granted Nov 22, 2016·50 cites·30 claims
- 0296US10000576B1Bispecific antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2018·Granted Jun 19, 2018·23 cites·30 claims
- 0396US9574010B2Stable heterodimeric antibody design with mutations in the Fc domainZYMEWORKS INC·Filed 2012·Granted Feb 21, 2017·48 cites·79 claims
- 0495US10457742B2Stable heterodimeric antibody design with mutations in the Fc domainZYMEWORKS INC·Filed 2017·Granted Oct 29, 2019·17 cites·32 claims
- 0595US9522876B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2014·Granted Dec 20, 2016·19 cites·48 claims
- 0692US9914785B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2013·Granted Mar 13, 2018·17 cites·15 claims
- 0792US9879086B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2015·Granted Jan 30, 2018·11 cites·90 claims
- 0891US11286293B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2018·Granted Mar 29, 2022·6 cites·25 claims
- 0991US11161915B2Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereofZYMEWORKS INC·Filed 2016·Granted Nov 2, 2021·7 cites·26 claims
- 1091US9388231B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2013·Granted Jul 12, 2016·16 cites·38 claims
- 1190US11306156B2Modified antigen binding polypeptide constructs and uses thereofZYMEWORKS INC·Filed 2015·Granted Apr 19, 2022·7 cites·37 claims
- 1290US11078296B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2018·Granted Aug 3, 2021·5 cites·12 claims
- 1390US10077298B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS INC·Filed 2013·Granted Sep 18, 2018·15 cites·22 claims
- 1490US9988460B2Crystal structures of heterodimeric Fc domainsZYMEWORKS INC·Filed 2017·Granted Jun 5, 2018·8 cites·15 claims
- 1589US11325981B2Bispecific antigen-binding constructs targeting Her2ZYMEWORKS INC·Filed 2018·Granted May 10, 2022·2 cites·19 claims
- 1689US10947319B2Bispecific antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2014·Granted Mar 16, 2021·5 cites·18 claims
- 1789US10155803B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2016·Granted Dec 18, 2018·3 cites·27 claims
- 1889US9732155B2Crystal structures of heterodimeric Fc domainsZYMEWORKS INC·Filed 2013·Granted Aug 15, 2017·12 cites·15 claims
- 1988US10875931B2Stable heterodimeric antibody design with mutations in the Fc domainZYMEWORKS INC·Filed 2017·Granted Dec 29, 2020·4 cites·8 claims
- 2087US11147886B2Drug-conjugated bi-specific antigen-binding constructsZYMEWORKS INC·Filed 2016·Granted Oct 19, 2021·3 cites·15 claims
- 2187US11000598B2Anti-HER2 biparatopic antibody-drug conjugates and methods of useZYMEWORKS INC·Filed 2019·Granted May 11, 2021·5 cites·17 claims
- 2285US11028182B2Antigen-binding constructs targeting HER2ZYMEWORKS INC·Filed 2016·Granted Jun 8, 2021·2 cites·28 claims
- 2385US9771573B2Methods of quantitating heavy and light chain polypeptide pairsZYMEWORKS INC·Filed 2013·Granted Sep 26, 2017·8 cites·36 claims
- 2483US10201614B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2014·Granted Feb 12, 2019·3 cites·38 claims
- 2581US10711051B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2018·Granted Jul 14, 2020·1 cites·21 claims
- 2680US11152081B2Methods for determining correlated residues in a protein or other biopolymer using molecular dynamicsZYMEWORKS INC·Filed 2016·Granted Oct 19, 2021·3 cites·7 claims
- 2780US10414822B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2018·Granted Sep 17, 2019·2 cites·34 claims
- 2879US10450378B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS INC·Filed 2015·Granted Oct 22, 2019·2 cites·61 claims
- 2978US10358479B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2016·Granted Jul 23, 2019·2 cites·24 claims
- 3077US10255409B2Systems and methods for in silico evaluation of polymersZYMEWORKS INC·Filed 2014·Granted Apr 9, 2019·9 cites·27 claims
- 3176US11208497B2Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereofZYMEWORKS INC·Filed 2014·Granted Dec 28, 2021·2 cites·39 claims
- 3276US11098105B2Heteromultimers with reduced or silenced effector functionZYMEWORKS INC·Filed 2014·Granted Aug 24, 2021·2 cites·16 claims
- 3375US10508154B2Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cellsZYMEWORKS INC·Filed 2016·Granted Dec 17, 2019·1 cites·37 claims
- 3474US11560422B2Sulfonamide-containing linkage systems for drug conjugatesZYMEWORKS INC·Filed 2014·Granted Jan 24, 2023·1 cites·38 claims
- 3573US10273303B2Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereofZYMEWORKS INC·Filed 2014·Granted Apr 30, 2019·2 cites·21 claims
- 3673US10239951B2Bispecific HER2 and HER3 antigen binding constructsZYMEWORKS INC·Filed 2014·Granted Mar 26, 2019·2 cites·20 claims
- 3771US7769573B2System and method for modeling interactionsZYMEWORKS INC·Filed 2006·Granted Aug 3, 2010·9 cites·19 claims
- 3871US2021317212A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2021·Application pending·0 cites
- 3969US2021277150A1STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAINZYMEWORKS INC·Filed 2020·Application pending·0 cites
- 4068US11248037B2Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2019·Granted Feb 15, 2022·0 cites·36 claims
- 4168US2021009659A1Multivalent heteromultimer scaffold design and constructsZYMEWORKS INC·Filed 2020·Application pending·0 cites
- 4265US2020087414A1STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAINZYMEWORKS INC·Filed 2019·Application pending·0 cites
- 4361US2021269553A1Methods using monovalent antigen binding constructs targeting her2ZYMEWORKS INC·Filed 2020·Application pending·0 cites
- 4461US2019248897A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2019·Application pending·0 cites
- 4561US2021260210A1Anti-her2 biparatopic antibody-drug conjugates and methods of useZYMEWORKS INC·Filed 2019·Application pending·0 cites
- 4659US2014154253A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS INC·Filed 2013·Application pending·0 cites
- 4758US2026042847A1Cysteine engineered antibody constructs, conjugates and methods of useZYMEWORKS INC·Filed 2022·Application pending·0 cites
- 4854US2023331809A1Fusion proteins comprising a ligand-receptor pair and a biologically functional proteinZYMEWORKS INC·Filed 2021·Application pending·0 cites
- 4954US2016114057A1Modular protein drug conjugate therapeuticZYMEWORKS INC·Filed 2014·Application pending·0 cites
- 5054US2013336973A1Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc DomainZYMEWORKS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 76 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ZYMEWORKS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →